Malgorzata Zakrzewska

Design of fully active FGF-1 variants with increased stability.

The many faces of protease-protein inhibitor interaction.

Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action.

Structural requirements of FGF-1 for receptor binding and translocation into cells.

FGF-1: from biology through engineering to potential medical applications.

Phosphorylation of fibroblast growth factor (FGF) receptor 1 at Ser777 by p38 mitogen-activated protein kinase regulates translocation of exogenous FGF1 to the cytosol and nucleus.

Structure of a highly stable mutant of human fibroblast growth factor 1.

Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.

Longer action means better drug: tuning up protein therapeutics.

Clathrin- and dynamin-independent endocytosis of FGFR3--implications for signalling.

Tailoring small proteins towards biomedical applications.

FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation.

Protease resistant variants of FGF1 with prolonged biological activity.

Nucleolin regulates phosphorylation and nuclear export of fibroblast growth factor 1 (FGF1).

Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells.

Identification of new FGF1 binding partners-Implications for its intracellular function.

Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.

High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.

High-Yield Site-Specific Conjugation of Fibroblast Growth Factor 1 with Monomethylauristatin E via Cysteine Flanked by Basic Residues.

The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding.

Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.

Nanodiamonds as "artificial proteins": Regulation of a cell signalling system using low nanomolar solutions of inorganic nanocrystals.

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1.

Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation.

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment.

Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling.

Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.

Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity.

FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent manner.

Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions.

Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1).

FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization.

Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential.